Research notes

Included in the Textile & Apparel basket at 20% weightage with a 12-month horizon and 15-20% expected upside.

Included in the Textile & Apparel basket at 20% weightage with a 12-month horizon and 15-20% expected upside.

Included in the Textile & Apparel basket at 20% weightage with a 12-month horizon and 15-20% expected upside, flagged as high risk.

Listed in the Focus Investment Ideas table with CMP Rs 1,700 and 18% upside.

Listed in the Focus Investment Ideas table with CMP Rs 1,937 and 19% upside.

Listed in the Focus Investment Ideas table with CMP Rs 1,774 and 20% upside.

Listed in the Focus Investment Ideas table with CMP Rs 4,399 and 40% upside.

Listed in the Focus Investment Ideas table with CMP Rs 321 and 34% upside on a one-year horizon.

The technical radar flags a GAIL October futures sell on a daily range breakdown, trading below the 200 DEMA with immediate resistance at 173.

The technical radar says a hammer candle formed on the daily chart with more momentum above 387 and immediate support at 373.

The technical conviction delivery idea says the stock has seen a weekly consolidation breakout with base shifting higher and RSI positively placed, recommending buy at CMP ₹1,771 with SL ₹1,717 for a one-week duration.

The note reports JSW Cement will absorb listed subsidiary Shiva Cement to form a unified platform with synergies.

The note reports Shiva Cement will merge into JSW Cement, with Shiva shareholders receiving 5 JSW Cement shares for every 41 Shiva shares.

The velocity idea says oral Wegovy could raise peptide API needs ~73x per patient and that Proclamation 11020 gives India a 0% tariff rate on specialty drug classes, with a 21% earnings CAGR expected over FY26-28; CMP ₹9,540, SL ₹8,870.

The note says Trent's 2QFY27 standalone revenue grew 22.5% YoY with 30 net store adds to 1,342 fashion stores, and models FY26-29E revenue/pre-IND AS EBITDA/Adj. PAT CAGR of 21%/26%/19%, implying 46% upside from CMP INR2,580; separately the derivatives section lists a Trent 2600 PE buy idea on short buildup.

The initiating coverage section says Molbio's Truenat point-of-care molecular platform, with 12,500+ devices across 90+ countries and 43 assays, plus digital pathology expansion, should drive an estimated 23% revenue CAGR and 50% PAT CAGR over FY26-29, with 19% upside from CMP INR1,503.

The note says mills have raised long product prices by INR1,500-2,000/ton, flat steel by INR800-2,000/ton and alloy steel round bars by INR2,000-2,500/ton from 1 Oct'26, tagging the view as Positive.

The note says IndusInd's net advances grew 11.2% YoY beating estimates while deposits rose 10.1% YoY missing estimates, with CASA at 28.0% and FCNR(B) mobilisation of USD3.51b, and tags the view as Positive.

The note says Axis Bank's 2QFY27 gross advances grew 22.7% YoY beating estimates while deposits rose 20.7% YoY missing estimates, with CASA mix at 36.5% and CD ratio at 95.4%, and tags the view as Positive.

The note says Kotak's 2QFY27 net advances grew 24.7% YoY and deposits 23.2% YoY, both above estimates aided by FCNR(B) flows, though CASA fell to 38.2%, and tags the view as Positive.

The report's intraday quant strategy gives a MAZDOCK Sell idea at close price 2076 with SL 2097 and target 2055.

The report's intraday quant strategy gives an IREDA Sell idea at close price 108.9 with SL 110 and target 107.9.

The report separately lists a derivatives 2600 PE option buy on Trent in the buying range 97-98 with SL 88 and target 116, citing Short Buildup.

The report lists a 1200 PE option buy on Dr Reddy's in the buying range 30-31 with SL 27 and target 37, citing Short Buildup.

The report lists a 1440 PE option buy on Prestige in the buying range 43-44 with SL 39 and target 52, citing Short Buildup.